07:00 , May 13, 2013 |  BioCentury  |  Regulation

Diagnostic survival test

Based on advice being given to the...
01:35 , May 2, 2013 |  BC Extra  |  Politics & Policy

MEDCAC mixed on cancer diagnostics

CMS's Medicare Evidence Development and Coverage Advisory Committee (MEDCAC) concluded on Wednesday that existing evidence is sufficient to confirm the clinical validity of DNA- or RNA- based testing to predict the tissue of origin for...
00:23 , Apr 27, 2013 |  BC Extra  |  Politics & Policy

CMS to discuss genetic tests for cancer

CMS released meeting material including an agenda and speaker list ahead of a May 1 meeting of its Medicare Evidence Development & Coverage Advisory Committee (MEDCAC) to discuss technology assessments for two types of genetic...
02:12 , Feb 14, 2013 |  BC Extra  |  Politics & Policy

CMS to assess genetic tests for cancer diagnosis

CMS's Medicare Evidence Development & Coverage Advisory Committee (MEDCAC) will meet on May 1 to discuss technology assessments for two types of genetic tests for cancer diagnosis. The committee will discuss the evidence for DNA-...
07:00 , Jun 11, 2012 |  BC Week In Review  |  Clinical News

CancerTYPE ID test diagnostic data

Researchers at the Sarah Cannon Research Institute reported data from 194 evaluable previously untreated patients with carcinoma of unknown primary origin showing that site-specific chemotherapy as directed by the CancerTYPE ID test significantly improved median...
07:00 , Jun 11, 2012 |  BC Week In Review  |  Clinical News

CancerTYPE ID test diagnostic data

bioMerieux's bioTheranostics Inc. subsidiary reported data from 122 metastatic tumor samples of unknown primary origin showing that the CancerTYPE ID test had a significantly greater overall accuracy for determining primary tumor site compared with immunohistochemistry...
07:00 , Jun 11, 2012 |  BioCentury  |  Finance

Highlights of weekly biotech stock moves

Regulatory milestones GenVec Inc. (NASDAQ:GNVC) lost a penny to $2.48 last week after the U.S. Department of Agriculture's Animal and Plant Health Inspection Service (APHIS) granted conditional approval for the biotech's first approved product, a...
00:50 , Jun 6, 2012 |  BC Extra  |  Clinical News

bioTheranostics reports data for molecular cancer classification assay

bioTheranostics Inc. reported data from a study showing that site-specific chemotherapy as directed by the CancerTYPE ID test significantly improved median overall survival (OS) vs. empiric therapy (12.5 vs. 4.7 months) in a subset of...
07:00 , Apr 16, 2012 |  BC Week In Review  |  Clinical News

CancerTYPE ID test: Pivotal trial data

bioMerieux's bioTheranostics Inc. subsidiary reported data from a pivotal trial in 790 tumor samples showing that the CancerTYPE ID test had 79% and 100% sensitivity and specificity, respectively, for correctly determining if a lung tumor...
07:00 , Aug 1, 2011 |  BC Week In Review  |  Clinical News

CancerTYPE ID test regulatory update

bioMerieux's bioTheranostics Inc. subsidiary said that an administrator for Medicare Part B issued a positive coverage determination to allow reimbursement for its CancerTYPE ID test to aid in the determination of the origin of a...